Selective RPE Laser Treatment (SRT) for Various Macular Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00403884|
Recruitment Status : Unknown
Verified November 2006 by University of Regensburg.
Recruitment status was: Active, not recruiting
First Posted : November 27, 2006
Last Update Posted : January 13, 2010
In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens. The macular diseases to be treated are drusen maculopathy and geographic atrophy due to age-related macular degeneration as well as diabetic macular edema and central serous chorioretinopathy.
The beneficial effect in laser treatment is thought to be associated with the restoration of a new barrier of retinal pigment epithelium cells. If this theory is true, the destruction of the photoreceptors causing visual field defects would be only an unwanted and unnecessary side effect. Thus, SRT is able to avoid these unintentional side effects and to achieve the benefit by just treating the RPE.
In this study the clinical effect of SRT for these diseases is evaluated on a long-term basis.
|Condition or disease||Intervention/treatment||Phase|
|Age-Related Macular Degeneration Diabetic Maculopathy Central Serous Chorioretinopathy||Procedure: Selective RPE laser treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Selective RPE Laser Treatment (SRT) for Various Macular Diseases|
|Study Start Date :||October 2004|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||August 2010|
- Procedure: Selective RPE laser treatment
interventional SRT laser treatmentOther Name: SRT vario, Medical Laser Center, Luebeck, Germany
- Visual acuity [ Time Frame: up to 2 years ]
- drusen reduction [ Time Frame: up to 2 years ]
- area of geographic atrophy [ Time Frame: up to 2 years ]
- reduction of retinal edema [ Time Frame: up to 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00403884
|University Eye Hospital Regensburg|
|Regensburg, Germany, 93042|
|Principal Investigator:||Carsten Framme, MD||University Eye Hospital Regensburg|